Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Clin Cancer Res. 2021 May 13;27(13):3744–3756. doi: 10.1158/1078-0432.CCR-21-0164

Fig. 3. AFM13 binding triggers enhanced cytotoxicity and cytokine secretion of cytokine induced ML NK cells and pre-activated-expanded CB NK cells.

Fig. 3.

(A) Specific killing of NK cells from relapsed Hodgkin Lymphoma (HL), healthy donors (HD) or expanded cord blood (CB) against Karpas 299 targets in presence or absence of AFM13 (100 μg/ml). E:T ratio of 10:1. (B) Peripheral blood (PB) cNK but mainly ML NK cells from HD exhibit enhanced cytotoxicity against CD30+ HuT-78 lymphoma targets when triggered with AFM13. (C) Preactivated expanded (P+E) CB-NK cells shows enhanced cytotoxicity against Karpas 299 targets compared to expanded (Exp) CB-NK in presence of different concentrations of AFM13. E:T ratio 5:1. (D) PB cNK and ML NK cells were stimulated HuT-78 cells (5:1 E:T ratio) and the production of IFN-γ, TNF, and CD107a degranulation was evaluated by Flow Cytometry. PB ML NK cells exhibit enhanced cytokine production and degranulation in response HuT-78 cells compared to cNK. In both cNK and ML NK cells AFM13 triggering significantly upregulated the production of IFN-γ, TNF, and CD107 degranulation. (E) cytokine production (IFN-γ and TNF) and CD107a degranulation by AFM loaded (100 μg/ml) P+E CB-NK cells vs. AFM13 loaded (100 μg/ml) expanded (Exp) NK cells co-cultured with Karpas 299 cells for 6 hours. E:T ratio of 1:1 ratio. Bars represent mean ± SEM. Two-way ANOVA with (A, B, D, E) Tukey or (C) Sidak post-hoc test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. n=6–10.